SCHEMBL7147041

SCHEMBL7147041

CN(CC(=O)N1CCC(C(=O)O)CC1)C(=O)[C@@H]1C[C@@H](S)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 6/20 0.60
MME P08473 2/20 0.60
ACE P12821 2/20 0.60
AKR1C3 P42330 4/20 0.48
AKR1C1 Q04828 1/20 0.48
CCR4 P51679 3/20 0.44
KMT2A Q03164 3/20 0.42
PKM P14618 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
MCL1 Q07820 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7137021 1.00 ECE1 (0.60) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7137022 1.00 ECE1 (0.60) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7138796 0.90 MME (0.58) ECE1MMEACEKMT2APKM
SCHEMBL7138798 0.90 MME (0.58) ECE1MMEACEKMT2APKM
SCHEMBL7135704 0.86 ECE1 (0.69) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7135702 0.86 ECE1 (0.69) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7143508 0.84 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7145236 0.84 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7143498 0.84 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7135958 0.84 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed